XBiotech Inc. (XBIT) Posts Earnings Results, Beats Estimates By $0.08 EPS
XBiotech Inc. (NASDAQ:XBIT) released its earnings results on Monday. The biopharmaceutical company reported ($0.38) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.46) by $0.08.
XBiotech (NASDAQ:XBIT) opened at 15.18 on Wednesday. The firm’s 50-day moving average price is $13.70 and its 200-day moving average price is $14.69. The stock’s market cap is $492.47 million. XBiotech has a 52 week low of $6.36 and a 52 week high of $25.00.
Separately, Zacks Investment Research cut XBiotech from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 20th.
A number of large investors have recently modified their holdings of XBIT. Paradigm Asset Management Co. LLC acquired a new position in XBiotech during the second quarter worth approximately $213,000. State Street Corp boosted its position in XBiotech by 508.7% in the second quarter. State Street Corp now owns 246,878 shares of the biopharmaceutical company’s stock worth $5,164,000 after buying an additional 206,318 shares in the last quarter. ProShare Advisors LLC boosted its position in XBiotech by 7.9% in the second quarter. ProShare Advisors LLC now owns 26,221 shares of the biopharmaceutical company’s stock worth $549,000 after buying an additional 1,909 shares in the last quarter. Rhumbline Advisers acquired a new position in XBiotech during the second quarter worth approximately $279,000. Finally, Teachers Advisors Inc. boosted its position in XBiotech by 353.6% in the second quarter. Teachers Advisors Inc. now owns 25,860 shares of the biopharmaceutical company’s stock worth $541,000 after buying an additional 20,159 shares in the last quarter. Institutional investors and hedge funds own 9.01% of the company’s stock.
XBiotech Company Profile
XBiotech Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing True Human monoclonal antibodies for treating a range of diseases. The Company focuses on bringing its lead product candidate, Xilonix (MABp1), to market. The Company has also developed a True Human monoclonal antibody discovery platform and manufacturing system.
Receive News & Stock Ratings for XBiotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XBiotech Inc. and related stocks with our FREE daily email newsletter.